Related Experiment Video

Updated: May 9, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Inhibition of cancer cell growth by BRCA2

Shao-Chun Wang1, Ruping Shao, Annie Y Pao

  • 1Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Cancer Research
|March 13, 2002
PubMed

Insights

The breast cancer gene BRCA2, beyond DNA repair, also inhibits cancer cell growth. Restoring wild-type BRCA2 function suppressed tumor development and cell proliferation in pancreatic cancer models.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The breast cancer susceptibility gene BRCA2 is known for its role in DNA repair.
  • Cells lacking functional BRCA2 exhibit DNA damage repair deficiencies.
  • The potential role of BRCA2 in regulating cell proliferation and suppressing oncogenesis is not fully understood.

Purpose of the Study:

  • To investigate whether BRCA2 possesses functions beyond DNA repair in suppressing oncogenesis.
  • To determine if BRCA2 can regulate cancer cell proliferation.
  • To explore the impact of reconstituting wild-type BRCA2 in a cancer cell line with a mutated BRCA2 gene.

Main Methods:

  • Reconstitution of wild-type BRCA2 protein expression in the Capan-1 pancreatic cancer cell line, which harbors a mutated BRCA2.
  • Expression was achieved in both constitutive and regulated manners.
  • Assessed the effects on cell proliferation in vitro and tumor growth in vivo.

Main Results:

  • Reconstitution of wild-type BRCA2 expression significantly inhibited cell proliferation in cultured Capan-1 cells.
  • Tumor growth in animal models was suppressed following the restoration of wild-type BRCA2.
  • These findings indicate a dual role for BRCA2 in both DNA repair and the inhibition of cancer cell growth.

Conclusions:

  • BRCA2 functions not only as a DNA repair protein but also as a suppressor of tumor development by inhibiting cancer cell proliferation.
  • This study expands the known functions of BRCA2, highlighting its importance in controlling cell growth pathways relevant to oncogenesis.
  • The findings suggest that targeting BRCA2-mediated cell growth inhibition could be a therapeutic strategy in cancers with BRCA2 mutations.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...